INCR Stock Analysis: Buy, Sell, or Hold?
INCR - Intercure Ltd. Ordinary Shares
$4.46
0.04 (0.90%)
▲
5d:
-4.09%
30d:
-18.46%
90d:
+361.7%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When INCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INCR is currently trading at $4.46, which is considered oversold relative to its 30-day fair value range of $4.74 to $5.41.
Technical Outlook: Technically, INCR is in a strong uptrend. The price is currently testing key support at $4.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INCR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.56 (+659.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INCR is in a strong uptrend. The price is currently testing key support at $4.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INCR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.56 (+659.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.74 -
$5.41
Company Quality Score
65/100
(BUY)
Options IV Signal
49th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 49th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 659.3% below Wall St target ($33.56)
- CAUTION: Bottoming setup, but lagging the sector by 12% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$4.74 -
$5.41
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.55
(12.2%)
Support & Resistance Levels
Support Level
$4.42
Resistance Level
$5.45
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.18
Wall Street Target
$33.56
(+659.3%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-84.7%
Profit Margin
-13.2%
Share & Embed Analysis
Last updated: October 22, 2026 10:03 AM ET
Data refreshes hourly during market hours. Next update: 11:03 AM
Data refreshes hourly during market hours. Next update: 11:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 59 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 50 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 61 BUY |
